The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and
severely affect patients with neuromuscular disorders. In a short period of time, it has already
caused reorganization of neuromuscular clinical care delivery and education, which will
likely have lasting effects on the field. This article reviews (1) potential neuromuscular
complications of COVID-19,(2) assessment and mitigation of COVID-19-related risk for
patients with preexisting neuromuscular disease,(3) guidance for management of …

COVID-19 infection has been reported to be associated with neurological complications
including neuromuscular symptoms/syndromes. The underlying mechanism is felt to be most
likely autoimmune, though direct neuroinvasion or neurotropism of the virus could also be
contributory. Acute cranial mononeuropathies, brachial plexopathy, peripheral
radiculoneuropathy (Guillain-Barre syndrome and its variants), and muscle damage have
been reported in association with the infection, and these can occur either during the course …